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Abstract A sizeable proportion of migraineurs in need of
preventive therapy do not signiﬁcantly beneﬁt from
monotherapy. The objective of the study is to conduct a
randomized controlled trial testing whether combination
therapy of topiramate and nortriptyline is useful in patients
who had less than 50% decrease in headache frequency
with the use of the single agents. Patients with episodic
migraine were enrolled if they had less than 50% reduction
in headache frequency after 8 weeks of using topiramate
(TPM) (100 mg/day) or nortriptyline (NTP) (30 mg/day).
They were randomized (blinded fashion) to have placebo
added to their regimen, or to receive the second medication
(combination therapy). Primary endpoint was decrease in
number of headache days at 6 weeks, relative to baseline,
comparing both groups. Secondary endpoint was propor-
tion of patients with at least 50% reduction in headache
frequency at 6 weeks relative to baseline. A total of 38
patients were randomized to receive combination therapy,
while 30 continued on monotherapy (with placebo) (six
drop outs in the combination group and three for each
single drug group). For the primary endpoint, mean and
standard deviation (SD) of reduction in headache fre-
quency were 4.6 (1.9) for those in polytherapy, relative to
3.5 (2.3) for those in monotherapy. Differences were sig-
niﬁcant (p\0.05]. Similarly, 78.3% of patients random-
ized to receive polytherapy had at least 50% headache
reduction, as compared to 37% in monotherapy (p\0.04).
Finally we conclude that combination therapy (of TPM and
NTP) is effective in patients with incomplete beneﬁt using
these agents in monotherapy.
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Introduction
Migraine is a chronic neurological disorder with episodic
attacks of headache and associated symptoms [1, 2]. The
disability of migraine can be severe and imposes a con-
siderable burden on the sufferer and the society [3–5].
Because migraine resembles both acute and chronic
conditions, pharmacological treatment is often divided into
acute and preventive modalities [6]. Preventive treatment is
recommended for patients with frequent or disabling
attacks [5]. Frequently used ﬁrst-choice medications for the
preventive treatment of migraine include beta-blockers,
tricyclic antidepressants, calcium channel antagonists, and
neuromodulators [7, 8]. When properly used, preventive
medications are associated with improvement in the quality
of life [9] and decreased disability [10]. Nonetheless, a
sizeable proportion of migraineurs in need of preventive
therapy do not signiﬁcantly beneﬁt from monotherapy (i.e.
do not experience meaningful reduction in headache fre-
quency) or experience side effects that impact adherence
[11].
Clinical experience and limited evidence suggests that
combination preventive therapy beneﬁts individuals with
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are not available. Accordingly, the objective of this study
was to conduct a randomized controlled trial testing whe-
ther combination therapy of topiramate and nortriptyline is
useful in patients who had less than 50% decrease in
headache frequency with the use of the single agents. We
hypothesized that, in patients with incomplete migraine
relief using monotherapy, polytherapy is associated with
improved outcomes as compared to maintaining
monotherapy.
Methods
Our sample consisted of 80 individuals (20–60 years of
age) selected from one outpatient headache clinic. All had
episodic migraine according to the Second Edition of the
International Classiﬁcation of headache disorder [12] for at
least 1 year. Sample was recruited during the years of 2005
and 2006. Of them, 40 were using Topiramate (TPM)
50 mg bid for nearly 6 weeks (labeled titration schedule).
Other 40 individuals were using nortriptyline (NTP)
30 mg/day for nearly 6 weeks (titration of 10 mg at
nighttime for 7 days, 20 mg for 7 days, and 30 mg
thereafter).
To be included in this study, patients had to have less
than 50% headache frequency improvement at 8 weeks,
relative to baseline, as documented by headache calendars.
Patients should also empirically consider that the beneﬁt of
preventive medication had not been adequate (meaning
they were not satisﬁed with their level of improvement).
Exclusion criteria include women not using stable contra-
ceptive methods for at least 3 months as well as patients
with less than 4 or with more than 12 headache days per
month. The chosen headache frequency limits as well as
the frequency of rescue medications consumption were
arbitrary. Additionally, patients with comorbid relevant
psychiatric or medical conditions were not included as
evaluated by a detailed ﬁrst time visit of 1 h in addition to
Hamilton anxiety and depression scales as well as Beck
inventory. Participants were patients consulting a tertiary
headache center, who were found to meet inclusion criteria
during a routine medical visit. This method was chosen to
mimic neurology clinical practice, since providers often
face complaints of incomplete migraine relief when
patients are using standard medications, and have to base
decisions with limited supportive evidence. Trial was
therefore conducted in a single headache center, in Rio de
Janeiro, Brazil.
After agreeing to participate (documented by signing an
Institutional Review Board (IRB) approved consent form),
patients originally using TPM in monotherapy were ran-
domized to also receive NTP or placebo at a 1:1 ratio,
using random number generation trough a software. They
were titrated to two capsules of NTP or matching placebo
after 1 week and three capsules during dinner for 6 weeks
(30 mg of NTP or matching placebo).
Patients using NTP in monotherapy (30 mg/day) added
TPM or placebo as follows: one capsule (25 mg or placebo
during breakfast) for 7 days; one capsule of 25 mg TPM or
matching placebo bid for 10 days; one capsule in the
morning and two at nighttime for 14 days; two capsules bid
thereafter. Accordingly, those randomized to receive TPM
reached a dose of 100 mg. The design was therefore par-
allel. After failure of monotherapy (run-in, open label and
prior to randomization), patients were randomized to con-
tinue in monotherapy (drug ? placebo) or to be switched
to polytherapy. Reasons to use TPM or NTP as initial
therapeutic options were based on the ﬁrst author’s expe-
rience and did not follow any speciﬁc characteristic of the
patients such as previous failure or use of pharmacological
classes.
All patients received emphatic education on the treat-
ment of migraine and received the study drugs for free,
which were the commercially available 25-mg capsules of
TPM and the 10-mg capsules of NTP. The placebo cap-
sules had the same appearance. Headache frequency and
severity was captured using detailed headache calendars,
and revised monthly. Rescue medications were allowed
and limited to twice a week since it is the maximum
allowed frequency of headache medications intake used as
routine by the study center. They consisted of a combina-
tion of a triptan plus a nonsteroidal anti-inﬂammatory drug.
The study was approved by an Investigational Review
Board.
Since this study was developed to mimic conditions
often used in clinical practice, we achieved endpoints after
6 weeks of therapeutic dose or around 10 weeks after
randomization. Endpoints were deﬁned a priori. Primary
endpoint was reduction in the number of headache days at
6 weeks versus baseline, comparing both the groups.
Secondary endpoint was proportion of patients with at
least 50% reduction in headache frequency, comparing
both the groups. At the termination visit (6 weeks)
patients were speciﬁcally prompted to report any adverse
events. Patients completed at least three visits in order to
be evaluated (one for initial prescription of the single
drug, one for evaluating the headache outcome with the
initial chosen drug, when the inclusion of the second drug
was carried out and a third visit to evaluate the outcomes
with the two drugs).
Statistical analyses
The study was powered a priori, for the primary endpoint.
We assumed a difference of 1.5 days between both groups
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ventive clinical trial studies. Using 1-sided T test we nee-
ded 38 patients per group to have a 80% power to detect a
difference at the 5% level. Descriptive statistic and sum-
mary tables were developed. Normality of data was
assessed using the Kolmogorov–Smirnov test. Data nec-
essary for the primary endpoint was found to follow a
normal distribution and were compared with the unpaired,
1-sided T test. For the secondary endpoint (proportions),
data were compared using the Chi-Squared test. Multiple
comparisons were not performed, therefore corrections
were not necessary. Due to sample size limitations, we did
not conduct sub-analyses or estimated response as a func-
tion of demographics or migraine features. Signiﬁcance
level was established at 5%.
Since assessment was conducted at 6 weeks only, we
conducted per-protocol analyses, since intent-to-treat
analyses do not apply (efﬁcacy was assessed at a single
point in time).
Results
Overall description
Table 1 describes the demographics and baseline fre-
quency of participants in group 1 (TPM), group 2 (NTP)
and overall. In group 1, 6 (15%) men and 34 (85%)
women were included (ages 22–57, mean 36 years). The
mean overall baseline headache frequency (HF) was
7 ± 3 headaches days/month. Among them, 23 (57.5%)
received NTP and 17 (42.5%) were randomized to receive
placebo. Group two included 9 (22.5%) men and 31
(17.5%) women (ages 20–60, mean 39 years) who had a
baseline mean HF of 9 ± 3 headaches days/month.
Among them, 21 (52.5%) received TPM and 19 (47.5%)
received placebo. None of the patients had comorbid
tension-type headache
Accordingly, a total of 44 patients (8 men and 36
women) were randomized to receive the combination of
TPM and NTP (23 received NTP and 21 received TPM).
Seventeen patients (2 men and 15 women) took TPM and
placebo and 19 (3 men and 16 women) had NPT and
placebo (Fig. 1).
Headache parameters
Reduction in headache frequency
Unless otherwise stated, we present means and SD of the
data. Mean reduction in headache frequency at follow-up
relative to baseline was signiﬁcantly higher in the combi-
nation group versus monotherapy [mean 4.6 (SD 1.9)
versus 3.5 (SD 2.3), p = 0.04]. When analyzing by sub-
group, headache frequency signiﬁcantly dropped in all
groups after randomization. In patients with previous
incomplete relieve to TPM that were randomized to have
NTP added, mean monthly headache frequency signiﬁ-
cantly dropped from a mean of 8.1 (SD 1.6) to 3.8 (SD 1.2)
(p\0.001). In those initially receiving NTP who had TPM
added, mean frequency dropped from 8.1 (SD 1.5) to 3.1
(SD 1.6), p\0.001. Nonetheless, those randomized to
have placebo added to their monotherapy also had a sig-
niﬁcant drop in their headache frequency, from 8.0 (SD
1.4) to 4.5 (SD 1.8) (p\0.001).
When comparing the reduction in headache frequency
across all three groups, those randomized to receive TPM
had a signiﬁcantly increased reduction in headache fre-
quency relative to those in placebo (mean 5.0 vs. 3.2,
p = 0.02). Those receiving NTP had a numerical but not
signiﬁcant reduction relative to placebo. Difference in
TPM and NTP were not signiﬁcant. Data are summarized
in Fig. 2.
Of patients initially treated with TPM who had added
NTP, 70% had at least 50% reduction in headache fre-
quency; for those who added TPM, 83.3% of them
achieved this substantial reduction. Together, 78.3% of
patients randomized to receive the combination of the two
drugs had at least 50% of headache reduction. For
TPM ? placebo users, 47% had at least 50% decreasing in
headache frequency. For NTP ? placebo users, 37% had at
least 50% reduction in headache frequency. Overall, dif-
ferences between switching to combination and continuing
in monotherapy were signiﬁcant (p = 0.04) (Fig. 3). The
use of rescue medications (RD), although not used as an
outcome comparator between the use of single drugs and
the combination was clearly restricted to twice a week and
did not reveal differences between groups. The average
consumption of RD decreased from 10.2 to 4.3 days per
Table 1 Demographic and
headache characteristics of
participants
* Age presented as
mean ± standard deviation
TPM ? NTP N = 44 TPM ? Placebo N = 17 NTP ? Placebo N = 19
Demographics 36 women (81.8%)
Ages 36 ± 9.55
15 women (88.2%)
Ages 35.7 ± 8.2
16 women (84.2%)
Ages 41.5 ± 6.72
8 men (18.2%)
Ages 36.6 ± 9.47
2 men (11.8%)
Ages 36–38
3 men (15.8%)
Ages 39.6 ± 6.77
Baseline headache
days/month
8.1 8 8
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group and from 9.6 to 4.6 in the NTP group.
Tolerability
Side effects among those who completed the treatment
period were mild and consisted of dry mouth, paresthesia,
weight loss, somnolence, weight gain, memory distur-
bances, hair loss and heartburn. Some patients presented
two or three side effects simultaneously. Table 2 summa-
rizes the incidence and characterization of the side effects
presented by patients of the three groups. However, data on
the occurrence of side effects among three female patients
of the NTP ? placebo group and two female patients of the
combination group were not found for analysis. There were
six drop outs in the combination group and six in the single
drug groups (3 for each treatment regimen). The patients
were lost to follow-up and reasons for dropping out were
not identiﬁed (Fig. 1). Therefore, we decided to gather side
effect proﬁle information for those who completed the
treatment period as presented in Table 2.
Discussion
Managing the migraine patient is sometimes difﬁcult,
especially when they are referred from the neurologist to
the headache specialist. Guidelines recommendations sug-
gest that the goal of preventive treatment is to reduce
headache frequency by at least 50%, based on the
assumption that this reduction is likely clinically mean-
ingful [13–15].
When a patient fails to respond as expected to appro-
priate therapy, or announces at the ﬁrst consultation that he
or she has already tried everything and nothing will work,
it is important to identify the reason or reasons that treat-
ment has failed. Among the several potential reasons,
inadequate pharmacotherapy is listed [16]. Inadequate
Assessed for eligibility 
(n=108) 
Excluded (n=28) 
Not meeting inclusion criteria (n=25) 
Patients with depression after TPM use 
(n=3) 
Analysed  
(n=20) 
Lost to follow-up: Unknown 
reasons (n=3) 
1 - Topiramate + NTP 
Allocated to intervention (n=23) 
Returned for evaluation (n=20) 
Lost to follow-up: Unknown 
reasons (n=3) 
2 - Topiramate + PLC 
Allocated to intervention (n=17) 
 Returned for evaluation (n=14) 
Allocation 
Analysis  Follow-Up
Randomized 
 (n=80) 
Enrollment 
Lost to follow-up: Unknown 
reasons (n=3) 
3 - Nortriptyline+ TPM 
Allocated to intervention (n=21) 
  Returned for evaluation (n=18) 
Lost to follow-up: Unknown 
reasons (n=3) 
4 - Nortriptyline+ PLC 
Allocated to intervention (n=19) 
 Returned for evaluation (n=16) 
Analysed  
(n=14) 
Analysed  
(n=18) 
Analysed  
(n=16) 
TPM – topiramate; NTP – nortriptyline; PLC - placebo 
Fig. 1 Participants ﬂow
diagram
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selected, if excessive initial doses are used, if ﬁnal doses
are inadequate, if the duration of treatment is too short, if
combination treatment is required, if the patient fails to
absorb the drug, or if the patient is noncompliant [16].
Accordingly, although monotherapy is usually recom-
mended, rational combination therapy is sometimes
necessary.
Herein we found patients that were properly diagnosed
and educated, and that had incomplete relief (measured by
less than 50% reduction in headache frequency and sub-
jective assessment of poor response) with adequate doses
of ﬁrst line medications, presenting signiﬁcant improve-
ment after being randomized to combination therapy, rel-
ative to the continuation on monotherapy (placebo added).
Tolerability was not an issue for most patients.
8.1 8.05 8
3.1
3.8
5.1 5
4.25
2.9
0
1
2
3
4
5
6
7
8
9
TPM added NTP added Placebo added
Baseline Follow-up Difference
*
*
* **
* p < 0.001 relative to baseline. ** p < 0.05 relative to placebo.  
Fig. 2 Mean number of
monthly headache days at
baseline and follow-up as a
function of treatment groups
70%
83%
78%
44%
57%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
TPM with NTP added NTP with TPM added NTP and TPM pooled NTP and Placebo TPM and placebo
TPM with NTP added NTP with TPM added NTP and TPM pooled
NTP and Placebo TPM and placebo
P < 0.05 for NTP and TPM pooled vs. NTP and placebo or TPM and placebo 
Fig. 3 Proportion of
individuals presenting at least
50% reduction in headache
frequency as a function of
treatment group
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123Strengths of this study include the blinded design (to the
best of our knowledge this is the ﬁrst study to test com-
bination vs. monotherapy of preventive medications in a
blinded fashion), similar to what has been used for acute
medications [16–20], as well as the use of medications that
are considered to be ﬁrst line for migraine, and are avail-
able as generics in several countries. In other words, we
tried to be at the same time rigorous, while mimicking a
‘‘real-life’’ situation.
This study has important limitations as well. First, the
sample size is small and did not allow multivariate com-
parisons or deﬁnitive conclusions whether one combination
regimen is better than the other (starting with TPM and
adding NTP or vice versa). More important, efﬁcacy was
assessed in a single time point, and not monthly for at least
3 months, as recommended by the IHS. Additionally, we
used doses that are on the lower side of what is recom-
mended for migraine prevention, i.e., 100–200 mg/day of
TPM and 50–150 mg/day of a tricyclic antidepressant. The
doses that we used could certainly be raised, either in mono
or in polytherapy. Nonetheless, we have previously
reported that tolerability is improved when combination
therapy is done in the context of lower doses of medication,
without apparent compromise of efﬁcacy [21, 22]. One
might even argue of whether the differences between
monotherapy versus polytherapy could have been artiﬁ-
cially inﬂated due to the superiority of TPM compared to
NTP as a preventive drug. In addition, higher doses of NTP
would have been more reasonable in terms of outcome
instead of adding TPM.
However, we elected to use the combination of TPM
and NTP based on the synergistic mechanism of actions
and due to the fact that, in Brazil, the concerns of gaining
weight are a daily strongly limiting factor in using usually
recommended doses of NTP, which are higher than 30 mg/
day. It is assumed that tricyclic antidepressants address the
serotonergic and noradrenergic systems, while topiramate
also modulates the glutamatergic and gabaergic systems.
Accordingly, the combination of both may provide better
efﬁcacy due to the action on various possible neurotrans-
mitter dysfunctions as suggested in migraine pathophysi-
ology [22].
Our results are expected and supported by limited evi-
dence. Pascual et al. tested the combination of TPM and
different beta-blockers in patients who did not respond to
the single use of medications [23]. Although the study was
not blinded, they found that 62% of patients had at lest
50% reduction in headache frequency. The authors sug-
gested that the combination could be useful due to the
multi target action of the two drugs combined.
Barriers for migraine adequate care are several and
important [24–26]. With the improvement in recognition
and diagnosis, as well as better access to adequate acute
medications, recent attention has been given to barriers of
proper preventive medication use [11]. A sizeable pro-
portion of migraineurs receiving preventive monotherapy
are incompletely satisﬁed with the efﬁcacy. Herein we
present evidence that adding a second compound is asso-
ciated with signiﬁcant improve in headache frequency.
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